Brief: Bioarctic Says Eisai Simulates Leqembi Sales To Reach JPY 250-280 Bln In FY 2027
25/03/2025 07:09
March 25 (Reuters) - BioArctic AB BIOAb.ST: EISAI SIMULATES LEQEMBI SALES TO REACH JPY 250-280 BILLION IN FY 2027 Source text: ID:nWkrbXk66x Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln